Who is sponsoring NCT03588611?

NCT03588611 is sponsored by Han Yaling, MD.

What condition does NCT03588611 study?

NCT03588611 studies Acute Coronary Syndrome.

What drugs are being tested in NCT03588611?

Interventions: Bivalirudin, Bivalirudin.

What is the status of NCT03588611?

NCT03588611 is currently COMPLETED.

Last reviewed 2021-08-09 · How we verify

Reduce Bolus Injection of Bivalirudin

NCT03588611 PHASE4 COMPLETED

There are fewer studies on the bleeding risk of the currently administered bivalirudin bolus injection dose and the safety of bivalirudin in patients with CKD. A non-inferiority, randomized, stratified controlled trial study has been conducted to evaluate the non-inferiority and safety of the low dose (80%) bolus injections of bivalirudin in patients with or without CKD.This study will provide a safe, effective and economical anticoagulation strategy.

Details

Lead sponsor	Han Yaling, MD
Phase	PHASE4
Status	COMPLETED
Enrolment	204
Start date	Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jun 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Acute Coronary Syndrome

Interventions

Bivalirudin
Bivalirudin

Countries

China